{"content":"<li class=\"n-box-item date-title\" data-end=\"1541998799\" data-start=\"1541912400\" data-txt=\"Monday, December 23, 2019\">Sunday, November 11, 2018</li><li class=\"n-box-item sa-box-item\" data-id=\"3408349\" data-ts=\"1541979813\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SAP\" target=\"_blank\">SAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3408349-sap-acquires-qualtrics-international-just-ipo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SAP acquires Qualtrics International just before IPO</a></h4><ul>\n<li>SAP (NYSE:<a href='https://seekingalpha.com/symbol/SAP' title='SAP AG'>SAP</a>) <a href=\"https://seekingalpha.com/pr/17329725-sap-se-acquire-qualtrics-international-inc-sees-experience-management-future-business\" target=\"_blank\">announced acquisition</a> of experience management software company Qualtrics International (<a href='https://seekingalpha.com/symbol/XM' title='Qualtrics International'>XM</a>) for $8B in cash just before its IPO. The company has secured funding for \u20ac7B to cover purchase price and acquisition costs.</li>\n<li>\"SAP already touches 77% of the world's transactions. When you  combine our operational data with Qualtrics' experience data, we will  accelerate the XM category with an end-to-end solution with immediate  global scale,\" said SAP CEO Bill McDermott.</li>\n<li>Qualtrics expects FY18 revenue of $400M+ and was valued at $2.5B based on their <a href=\"https://seekingalpha.com/news/3405302-surveymonkey-competitor-sets-ipo-price-range\" target=\"_blank\">latest private funding round</a>.</li>\n<li>Qualtrics CEO Ryan Smith will continue to lead the company and will retain the branding.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3408349\" data-linked=\"SAP acquires Qualtrics International just before IPO\" data-tweet=\"$SAP $SAP $XM - SAP acquires Qualtrics International just before IPO https://seekingalpha.com/news/3408349-sap-acquires-qualtrics-international-just-ipo?source=tweet\" data-url=\"https://seekingalpha.com/news/3408349-sap-acquires-qualtrics-international-just-ipo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3408348\" data-ts=\"1541977212\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATHN\" target=\"_blank\">ATHN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3408348-athenahealth-sale-sealed-for-5_5b\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Athenahealth sale sealed for $5.5B</a></h4><ul>\n<li>\n<a href=\"https://www.cnbc.com/2018/11/11/veritas-capital-elliott-clinch-5point5-billion-acquisition-of-athenahealth.html?__source=twitter%7Cmain\" target=\"_blank\">According to Reuters</a>, P-E player Veritas Capital and hedge fund Elliott Management have teamed to purchase Athenahealth (NASDAQ:<a href='https://seekingalpha.com/symbol/ATHN' title='athenahealth, Inc.'>ATHN</a>) for $5.5B in cash, or roughly $135 per share (Friday close was $120.35).</li>\n<li>The official announcement is expected tomorrow.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3408348\" data-linked=\"Athenahealth sale sealed for $5.5B\" data-tweet=\"$ATHN - Athenahealth sale sealed for $5.5B https://seekingalpha.com/news/3408348-athenahealth-sale-sealed-for-5_5b?source=tweet\" data-url=\"https://seekingalpha.com/news/3408348-athenahealth-sale-sealed-for-5_5b\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3408347\" data-ts=\"1541971086\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMRN\" target=\"_blank\">AMRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3408347-amarins-vascepa-reduced-major-adverse-cardiovascular-events-25-in-large-scale-reduce-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amarin&#39;s Vascepa reduced major adverse cardiovascular events by 25% in large-scale REDUCE-IT study</a></h4><ul> <li>\n<a href=\"https://seekingalpha.com/pr/17329716-vascepa-icosapent-ethyl-26-percent-reduction-key-secondary-composite-endpoint-cardiovascular\" target=\"_blank\">Results </a>from the 8,179-subject REDUCE-IT study evaluating Amarin's (NASDAQ:<a href='https://seekingalpha.com/symbol/AMRN' title='Amarin Corporation PLC'>AMRN</a>) Vascepa (icosapent ethyl) in statin-treated adults with elevated cardiovascular &#40;CV&#41; risk showed a significant treatment effect.</li> <li>The data were presented at the AHA Scientific Sessions in Chicago and simultaneously <a href=\"https://www.nejm.org/doi/full/10.1056/NEJMoa1812792\" target=\"_blank\">published </a>in the <em>New England Journal of Medicine</em>.</li> <li>\n<a href=\"https://clinicaltrials.gov/ct2/show/NCT01492361?term=reduce-it&amp;rank=1\" target=\"_blank\">REDUCE-IT</a> assessed 4 g/day of Vascepa over a median of 4.9 years. It achieved the primary endpoint of a statistically valid 25% (hazard ratio = 0.75) reduction in a composite of cardiovascular death, nonfatal heart attack, nonfatal stroke, coronary revascularization and unstable angina requiring hospitalization compared to statin therapy alone.</li> <li>Patients receiving Vascepa on top of statin therapy experienced 31% less risk of a heart attack, 35% less risk of urgent/emergent revascularization (stent or bypass surgery), 20% less risk of CV death, 32% less risk of hospitalization for unstable angina and 28% less risk of stroke. The risk of total mortality (CV and non-CV) was reduced 13%.</li> <li>The CV benefits did not appear to significantly influenced by triglyceride levels between 135 mg/dL and 499 mg/dL at baseline, the targeted patient population for the company's planned supplemental marketing application on tap for early 2019 [Vascepa is currently approved in the U.S. for patients with severe hypertriglyceridemia (at least 500 mg/dL)].</li> <li>The company emphasizes the low cost of Vascepa compared to alternatives, with a monthly copay of $9.99 or less and the cost of a 90-day supply for as little as $9, depending on the type of insurance coverage.</li> <li>Management says it is in the process of expanding its U.S. salesforce to over 400 headcount.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3392323-amarin-reports-positive-results-reduce-study-shares-307-percent-premarket\" target=\"_blank\">Amarin reports positive results from REDUCE-IT study; shares up 307% premarket</a> (Sept. 24)</li>\n<li>\n<strong>Update</strong>: Shares are up <font color=\"green\">1%</font> premarket on Monday on modest volume.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3408347\" data-linked=\"Amarin&#39;s Vascepa reduced major adverse cardiovascular events by 25% in large-scale REDUCE-IT study\" data-tweet=\"$AMRN - Amarin&#39;s Vascepa reduced major adverse cardiovascular events by 25% in large-scale REDUCE-IT study https://seekingalpha.com/news/3408347-amarins-vascepa-reduced-major-adverse-cardiovascular-events-25-in-large-scale-reduce-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3408347-amarins-vascepa-reduced-major-adverse-cardiovascular-events-25-in-large-scale-reduce-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>34&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":3,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}